The US Patent and Trademark Office (USPTO) has granted a patent to Pearl Therapeutics' co-suspension formulation technology for inhaled combinations. The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl's ...
The US Patent and Trademark Office (USPTO) has granted new patent No. #8241330 to Lanx's Aspen MIS Fusion system, designed to support posterolateral fusions and interbody fusions. The Aspen system features proprietary spiked fixation ...
Tags: USPTO, MIS Fusion system, posterolateral fusions, interbody fusions
The US Patent and Trademark Office (USPTO) has granted a new Patent No. 8,298,554 to Amarin's pharmaceutical composition of ultra pure omega-3 fatty acid product. The patent covers the claims related to application No.12/769,885 for the ...
Tags: ultra pure omega-3 fatty acid product, vascepa capsules, icosapent ethyl
The US Patent and Trademark Office (USPTO) has granted a US Patent NO 8,185,485 B2 to Lifeline Biotechnologies' device used for analyzing thermal data based on breast surface temperature for the detection for use in determining cancerous ...
Tags: USPTO, Lifeline Biotechnologies'device, analyzing, surface temperature
Global specialty chemicals company Eastman Chemical has been assigned a patent number 8,287,970 for ‘plastic baby bottles, other blow molded articles, and processes for their manufacture.’ The patent has been developed by ...
Tags: baby bottles, advanced materials, chemicals and fibers
The US Patent and Trademark Office (USPTO) has granted a patent for the use of Aeterna Zentaris' oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency (AGHD). AEZS-130, which has been granted ...
Tags: AEZS-130, growth hormone deficiency, AGHD
Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office. The patent covers the synergistic effects of combination therapies containing COTI-2 and members of ...
Tags: oncology drug, COTI-2, anti cancer agents
Coronado Biosciences has received notice of allowance for US patent application covering CNDO-109, from the US Patent and Trademark Office (USPTO). The patent is entitled, Method for activating natural killer cells by tumor cell ...
Tags: CNDO-109, cancer cells, AML
Corgenix Medical has received additional patent covering its AspirinWorks technology from the US Patent and Trademark Office. The patent is issued for the AspirinWorks Test Kit, which measures thromboxane metabolites in urine to evaluate ...
Tags: AspirinWorks technology, AspirinWorks test kit, Corgenix Medical
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
The US Patent and Trademark Office (USPTO) has granted two new patents including Patent No. 8,793,727 and 8,293,728 to Amarin's ultra pure omega-3 fatty acid product. The patents include application No.12/702,889 and 13/349,153 for ...
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system. The patent application No.13/032,029 covers claims for ...
Tags: siRNA delivery system, US Patent, dynamic polyconjugate, DPC platform
Alitair Pharmaceuticals has gained a notice of allowance from the US Patent and Trademark Office for its ion exchange resin platform drug delivery technology, REA. Alitair has out-licensed two product candidates utilizing its REA platform ...
Tags: Alitair Pharmaceuticals, REA Drug Delivery Technology, US Patent
The US Patent and Trademark Office (USPTO) has granted three new patents to A.P. Pharma's new APF530 drug delivery candidate. The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset ...
Tags: US Patent, A.P.Pharma, APF530 drug delivery candidate, New Drug Delivery
The US Patent and Trademark Office (USPTO) has issued two additional patents to AcelRx Pharmaceuticals' sufentanil NanoTab pain products. The patent entitled Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment ...
Tags: AcelRx Pharmaceuticals, NanoTab pain products, two additional patents